B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. - Wikidata - wikimedia - TriplyDB

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

http://www.wikidata.org/entity/Q37301864

about

Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.B7-H3 role in the immune landscape of cancer.B7-H3 in tumors: friend or foe for tumor immunity?Reduced sB7-H3 Expression in the Peripheral Blood of Systemic Lupus Erythematosus Patients.Tunicamycin inhibits colon carcinoma growth and aggressiveness via modulation of the ERK-JNK-mediated AKT/mTOR signaling pathway.B7H3 As a Promoter of Metastasis and Promising Therapeutic Target Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody

P2860

Q34548319-42688D49-A1BC-4A97-A359-3062EB22BB1C Q38670099-63209B69-43F2-408C-9DB7-597BF9CA14E3 Q39427326-F1761233-6032-4F18-8601-F1D53973A7E6 Q47233613-F852BFB7-25A5-436A-AFC1-795780D1A6F7 Q49176886-432B507E-3D66-43B2-B103-5B85A74F5324 Q49981787-9A57E0CF-79D3-4C10-A9D8-FC5104FD1761 Q57176931-AC936446-D8E2-4D05-8F32-216D17B4834C Q58697139-55AC5A85-4B6D-4F1F-9866-E69C905C6C40

P2860

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

http://www.wikidata.org/entity/Q37301864

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

@en

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

@nl

type

label

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

@en

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

@nl

prefLabel

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

@en

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

@nl

P1433

Q37301864-BEF66888-F252-4DF8-B5BC-0D0D2029E00E

P1476

Q37301864-2D2EB1F0-375C-4DE2-BA16-87437776CBE5

P2093

Q37301864-31C51555-4B72-41C9-BD26-44372984412A

Q37301864-560D35DD-40A5-4341-B701-6BD57B440E24

Q37301864-599EBD6E-CE0B-46F2-BE2E-DF891F4E5D57

Q37301864-71509B6B-D05F-4A1F-A56F-E517E3BFEF64

Q37301864-94FF4479-8AC5-40FF-9F50-E1F3EDC37FA9

Q37301864-B8357B3F-0F7E-403C-8D7B-3FA1217FC62D

Q37301864-BC80D2F4-0ADD-4D2A-A22F-C8D1E867ADD7

Q37301864-C7A9409C-BDB3-4C3B-9685-DEAAD507C06E

Q37301864-E9CCA3E8-EC8F-4991-8AA7-277F086CC7D2

Q37301864-FF8337FC-AE2C-4EF1-A8DA-987F444343DB

P2860

Q37301864-012D75EB-321F-435A-B652-F718C450B157

Q37301864-08504B37-7EBC-45DF-BA61-3BE54B57B859

Q37301864-16128005-9CA9-434F-855C-8AADD3F8DE8E

Q37301864-1A1EC490-971D-4395-9C46-2E90F7CE98D1

Q37301864-258DE8A5-2D24-49AC-A9DD-EE1A582B527D

Q37301864-2D14B53F-CCE1-4904-8B61-36A9889A8F22

Q37301864-2F7CD545-FE99-4A34-AA35-0E38853BF3B2

Q37301864-32A3D270-D843-4310-8002-840120C43D54

Q37301864-3C8554FE-6B6E-4BB3-BD75-367893421B4C

Q37301864-40027EDE-9851-4D74-BA5B-74D154293137

P304

Q37301864-99B39580-1923-4647-AD46-FF1F3712BAA3

P31

Q37301864-56516B69-6747-4141-8658-8381EEC485AA

P356

Q37301864-C7EEAFC8-44F9-4E1C-956A-4CF7DCF56FE1

P407

Q37301864-9027F936-8989-4E16-ABAF-1BAD707AE246

P433

Q37301864-F3DA22DE-958F-4846-AD6F-23B820D7ADC9

P478

Q37301864-13E52AC9-95C3-4DCB-AF79-7C2EB79FD954

P577

Q37301864-6490EA09-B446-45E9-93BF-BCDE50CA25FB

P698

Q37301864-7CD34967-DCB2-4342-A409-DB2F282D1FAE

P921

Q37301864-EF6D837C-650F-4B95-9D11-E5B2B6E5EF23

P932

Q37301864-9DB75F7D-93BD-4C37-8DD4-0202DFD4D16E

P356

ONCOTARGET.8784

P1433

P1476

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

@en

P2093

Changzhen Liu

http://www.w3.org/2001/XMLSchema#string

Chenghai Zhao

http://www.w3.org/2001/XMLSchema#string

Hua Tao

http://www.w3.org/2001/XMLSchema#string

Huamin Han

http://www.w3.org/2001/XMLSchema#string

Jia Cai

http://www.w3.org/2001/XMLSchema#string

Juan Ma

http://www.w3.org/2001/XMLSchema#string

Man Zhang

http://www.w3.org/2001/XMLSchema#string

Pan Ma

http://www.w3.org/2001/XMLSchema#string

Weigang Xiu

http://www.w3.org/2001/XMLSchema#string

Xin Xue

http://www.w3.org/2001/XMLSchema#string

P2860

The Evolution of T-cell Therapies for Solid Malignancies

The blockade of immune checkpoints in cancer immunotherapy

The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cancer immunotherapy comes of age

The expression, function, and clinical relevance of B7 family members in cancer.

A simple and sensitive method for measuring tumor-specific T cell cytotoxicity.

Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients.

P304

29480-29491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8784

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27121051

http://www.w3.org/2001/XMLSchema#string

P921

P932

5045411

http://www.w3.org/2001/XMLSchema#string